163 related articles for article (PubMed ID: 38217831)
1. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
2. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
3. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
4. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
5. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
[TBL] [Abstract][Full Text] [Related]
6. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
Tan W; Zhang K; Chen X; Yang L; Zhu S; Wei Y; Xie Z; Chen Y; Shang C
J Adv Res; 2023 Feb; 44():173-183. PubMed ID: 36725188
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1α Pathway.
Zhang X; Han K; Yuan DH; Meng CY
DNA Cell Biol; 2017 Apr; 36(4):256-263. PubMed ID: 28191864
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
10. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
[TBL] [Abstract][Full Text] [Related]
11. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract][Full Text] [Related]
12. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
14. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma.
Shimokawa M; Yoshizumi T; Itoh S; Iseda N; Sakata K; Yugawa K; Toshima T; Harada N; Ikegami T; Mori M
Cancer Sci; 2020 Apr; 111(4):1228-1240. PubMed ID: 31968140
[TBL] [Abstract][Full Text] [Related]
15. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma.
Liu P; Han B; Zhang Y; Wang X
Comput Intell Neurosci; 2022; 2022():7102500. PubMed ID: 35720901
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma.
Tada M; Yokosuka O; Fukai K; Chiba T; Imazeki F; Tokuhisa T; Saisho H
J Hepatol; 2005 Apr; 42(4):511-9. PubMed ID: 15763338
[TBL] [Abstract][Full Text] [Related]
18. METTL3-m
Wang L; Yang Q; Zhou Q; Fang F; Lei K; Liu Z; Zheng G; Zhu L; Huo J; Li X; Peng S; Kuang M; Lin S; Huang M; Xu L
Cancer Lett; 2023 Apr; 559():216122. PubMed ID: 36898427
[TBL] [Abstract][Full Text] [Related]
19. Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.
Wu Z; Wang J
Discov Med; 2024 Jan; 36(180):199-208. PubMed ID: 38273760
[TBL] [Abstract][Full Text] [Related]
20. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]